Library — CHDR

Search

Filter

The bioavailability of digoxin from three oral formulations measured by a specific h.p.l.c. assay.

Cohen AF, Kroon R, Schoemaker HC, Breimer DD, Van Vliet-Verbeek A, Brandenburg HC

British journal of clinical pharmacology, 1993 Jan; 35(2):136-42

View publication
Characterization of glutathione conjugation in humans: stereoselectivity in plasma elimination pharmacokinetics and urinary excretion of (R)- and (S)-2-bromoisovalerylurea in healthy volunteers.

Mulders TM, Venizelos V, Schoemaker R, Cohen AF, Breimer DD, Mulder GJ

Clinical pharmacology and therapeutics, 1992 Dec; 53(1):49-58

View publication
Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise.

de Boer A, Kluft C, Dooijewaard G, Kasper FJ, Kroon JM, Breimer DD, Stiekema JC, Cohen AF

Thrombosis and haemostasis, 1992 Nov; 68(5):550-5

View publication
Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers.

Kroon C, ten Hove WR, de Boer A, Kroon JM, van der Pol JM, Harthoorn-Lasthuizen EJ, Schoemaker HC, van der Meer FJ, Cohen AF

Circulation, 1992 Oct; 86(5):1370-5

View publication
Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers.

van Steveninck AL, Verver S, Schoemaker HC, Pieters MS, Kroon R, Breimer DD, Cohen AF

Clinical pharmacology and therapeutics, 1992 Sep; 52(4):402-8

View publication
Diurnal rhythm in anticoagulant effect of heparin during a low dose constant rate infusion. A study in healthy volunteers.

Krulder JW, de Boer A, van den Besselaar AM, Cohen AF, Schoemaker HC, Briët E, Meinders AE

Thrombosis and haemostasis, 1992 Jul; 68(1):30-2

View publication
Pronounced effects of the combination of a new thromboxane antagonist (GR32191) and heparin on bleeding time in man.

de Boer A, Kroon JM, Kroon C, van Vliet A, Schoemaker HC, Breimer DD, Donoghue S, Cohen AF

Thrombosis and haemostasis, 1992 Jul; 68(1):24-9

View publication
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers.

Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M

Clinical pharmacology and therapeutics, 1992 May; 51(6):715-28

View publication
A multicentre trial of the aldose-reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group.

Macleod AF, Boulton AJ, Owens DR, Van Rooy P, Van Gerven JM, Macrury S, Scarpello JH, Segers O, Heller SR, Van Der Veen EA

Diabete & metabolisme, 1992 Apr; 18(1):14-20

View publication

«
1
2
...
63
64
65
66
67
68
69
70
71
»